Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | BI 905711 |
Synonyms | |
Therapy Description |
BI 905711 is a bispecific antibody that binds to and targets TRAILR2 and CDH17, potentially resulting in antitumor activity (Ann Oncol (2022) 33 (suppl_7): S136-S196). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
BI 905711 | BI-905711|BI905711 | BI 905711 is a bispecific antibody that binds to and targets TRAILR2 and CDH17, potentially resulting in antitumor activity (Ann Oncol (2022) 33 (suppl_7): S136-S196). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT04137289 | Phase I | BI 905711 | A First-in-human Phase Ia/b, Open Label, Multicentre, Dose Escalation Study of BI 905711 in Patients With Advanced Gastrointestinal Cancers | Completed | USA | FRA | ESP | DEU | BEL | 3 |